Frick M H, Pörsti P
Br Med J. 1976 May 1;1(6017):1046-8. doi: 10.1136/bmj.1.6017.1046.
The antihypertensive effect of labetalol, a new alpha- and beta-adrenoceptor inhibiting agent, was studied in 20 patients in a double-blind crossover trial. A dose of 300 mg daily reduced blood pressure only moderately in the supine position, though in the sitting and standing positions the effect was more pronounced. A dose of 600 mg daily produced statistically significant and clinically relevant reductions in blood pressure in all positions studied. The effect on heart rate was small and of significance only in reducing the heart rate increment due to a change in posture. Side effects were mild: only one patient complained of postural dizziness with the higher dose. We conclude that labetalol is useful in the treatment of mild and moderately severe hypertension.
新型α和β肾上腺素能受体抑制剂拉贝洛尔的降压作用在20例患者中进行了双盲交叉试验研究。每日300毫克的剂量仅使仰卧位血压有适度降低,不过在坐位和立位时效果更明显。每日600毫克的剂量在所有研究体位均产生了具有统计学意义且临床相关的血压降低。对心率的影响较小,仅在减少因姿势改变引起的心率增加方面具有显著意义。副作用轻微:仅1例患者在服用较高剂量时抱怨有体位性头晕。我们得出结论,拉贝洛尔可用于治疗轻度和中度重度高血压。